Du Yongxing, Duan Yunjie, Zhang Lipeng, Gu Zongting, Zheng Xiaohao, Li Zongze, Wang Chengfeng
State Key Laboratory of Molecular Oncology and Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Burns and Plastic Surgery, The Fourth Medical Center of PLA General Hospital, Beijing, China.
Front Oncol. 2022 May 30;12:890587. doi: 10.3389/fonc.2022.890587. eCollection 2022.
The incidence of multiple primary carcinomas (MPCs), which are defined as two or more malignancies detected in an individual person, is gradually increasing around the world. According to the timing of diagnosis for each constituent tumor, MPCs are classified into 2 categories: synchronous MPCs if constituent tumors emerge simultaneously or within 6 months or metachronous MPCs otherwise. In this report, we describe our recent observation and treatment of a female patient with synchronous primary esophagogastric junction adenocarcinoma, duodenal adenocarcinoma and pancreatic ductal adenocarcinoma (PDAC). To the best of our knowledge, this combination has not yet been reported in the literature. A crucial aspect is the decision regarding which tumor to treat initially and how to schedule further treatments according to individual tumor hazards. Our multidisciplinary team devised an individualized treatment regimen for this patient. The patient ultimately achieved an overall survival time of 18 months, which was much longer than the median survival time (6~11 months) of patients with locally advanced pancreatic cancer. Moreover, treating this rare combination raised a series of diagnostic, etiological and therapeutic questions, motivating us to carry out a critical review of the literature. In summary, an individualized treatment strategy with input from a dedicated multidisciplinary team and consideration of all options at different points along the disease trajectory is essential to optimize outcomes for patients with MPC.
多原发性癌(MPC)定义为在同一个体中检测到的两种或更多种恶性肿瘤,其发病率在全球范围内正逐渐上升。根据每个组成肿瘤的诊断时间,MPC可分为两类:如果组成肿瘤同时出现或在6个月内出现,则为同步MPC;否则为异时性MPC。在本报告中,我们描述了我们最近对一名患有同步原发性食管胃交界腺癌、十二指肠腺癌和胰腺导管腺癌(PDAC)的女性患者的观察和治疗情况。据我们所知,这种组合在文献中尚未见报道。一个关键问题是决定首先治疗哪个肿瘤,以及如何根据个体肿瘤风险安排进一步的治疗。我们的多学科团队为该患者制定了个性化的治疗方案。该患者最终实现了18个月的总生存时间,这比局部晚期胰腺癌患者的中位生存时间(6至11个月)长得多。此外,治疗这种罕见的组合引发了一系列诊断、病因和治疗方面的问题,促使我们对文献进行批判性回顾。总之,由专门的多学科团队提供意见并在疾病发展过程的不同阶段考虑所有选择的个性化治疗策略对于优化MPC患者的治疗效果至关重要。